Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Blood Advances|June 18, 2024
Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS interventionFateeha Furqan, Vineel Bhatlapenumarthi, Binod Dhakal, et al.British Journal of Haematology|September 19, 2022
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphomaFateeha Furqan, Kwang W Ahn, Yue Chen, et al.Transplantation and Cellular Therapy|June 13, 2024
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in MyelomaWilliam Wesson, Danai Dima, Nahid Suleman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2025
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell LymphomaNirav N Shah, Alfredo S Colina, Bryon D Johnson, et al.American Journal of Hematology|April 15, 2025
Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage TreatmentsFateeha Furqan, Kwang W Ahn, Manmeet Kaur, et al.Blood Advances|August 18, 2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohortJackson T Bowers, Jacob Anna, Steven M Bair, et al.Blood|February 3, 2021
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphomaPaolo Strati, Sairah Ahmed, Fateeha Furqan, et al.Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.Pageof 2